1 trial site in N.Z.

http://lctglobal.ongoing.co.nz/uploa...9s%20study.pdf

http://lctglobal.ongoing.co.nz/news/asx-announcements

Evaluation of the patients at 42 weeks post-implant showed a clinically and statistically significant improvement in their neurological scores from their pre-implant baseline. That improvement is equivalent to approximately 5 years of Parkinson’s disease remission

http://lctglobal.com/upload/news/new...O%20update.pdf



http://www.lctglobal.com/upload/pres...0the%20AGM.pdf

Filed new patent in USA
•
United States Patent and Trademark Office
•
Application Number 62/162,390
•
Treatment of CNS disease with encapsulated inducible choroid
plexus cells
•
Date 15/05/2015

I just say, very exciting news. The document in the first link above, says:

...In all four patients the 42 week
post-implant data show a clinically and
statistically significant improvement in
the patients’ neurological score from
their pre-implant baseline (Figure 1).
UPDRS score increases by 4-5 points
each year as Parkinson’s disease progresses. NTCELL’s ability to decrease UPDRS represents approximately 5 years
of Parkinson’s disease remission and is maintained 74 weeks after NTCELL implant in the first patient.
NTCELL treatment has stopped the progression of Parkinson’s disease as measured by globally accepted and
validated neurological rating scales in all four patients. All remain well, and there are no safety concerns...